

Struggling with Tourette's Disorder?



NOW ENROLLING: The Phase 3 D1AMOND study of adults, adolescents, and children with Tourette's Disorder

Tourette's Disorder affects millions of children, adolescents, and adults around the world. Currently approved therapies for Tourette's Disorder sometimes come with undesirable side effects, so there is a need for more research for this condition.

Scientists are investigating a study drug called ecopipam for adults, adolescents, and children with Tourette's Disorder. A study drug is one that is not yet approved for use by the general public. Ecopipam is designed to function differently than the currently approved therapies for individuals with Tourette's Disorder. Scientists want to find out how it works over time and how safe it is for children, adolescents, and adults with Tourette's Disorder.

Pharmaceutical companies use clinical studies like this one to learn more about study drugs before they are made available to the public. Study participants can help us in this important research.

To qualify for this research study, you must:

- Be at least 6 years old
- Weigh at least 18 kg (39.6 lbs)
- Have been diagnosed with Tourette's Disorder
- Have both motor and vocal tics

This is not a complete list of study requirements. The study doctor will review the full study requirements with you.

There is no cost to participate in this study. You do not have to pay for the study drug, study supplies, or tests that are part of the clinical study.

Ask your doctor if you are eligible to participate in the Phase 3 D1AMOND study.

EARLY TREATMENT CENTER
MICHIGAN CLINICAL RESEARCH INSTITUTE PC

DAEHO KIM
STUDY COORDINATOR
DAEHO@EARLYTREATMENT.ORG

3001 PLYMOUTH ROAD, SUITE 107
ANN ARBOR, MI 48105
734.834.8954
EARLYTREATMENT.ORG


D1AMOND
PHASE 3 